Monopar Therapeutics Quarterly Cash and Cash Equivalents, Period Increase (Decrease) in USD from Q1 2017 to Q1 2022
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.
-
Summary
-
Monopar Therapeutics quarterly/annual Cash and Cash Equivalents, Period Increase (Decrease) history and growth rate from Q1 2017 to Q1 2022.
- Monopar Therapeutics Cash and Cash Equivalents, Period Increase (Decrease) for the quarter ending March 31, 2022 was -$2.48M, a 128% decline year-over-year.
- Monopar Therapeutics annual Cash and Cash Equivalents, Period Increase (Decrease) for 2020 was $3.52M, a 44.3% decline from 2019.
- Monopar Therapeutics annual Cash and Cash Equivalents, Period Increase (Decrease) for 2019 was $6.32M.
- Monopar Therapeutics annual Cash and Cash Equivalents, Period Increase (Decrease) for 2018 was -$2.89M, a 142% decline from 2017.
Cash and Cash Equivalents, Period Increase (Decrease), Quarterly (USD)
Cash and Cash Equivalents, Period Increase (Decrease), YoY Quarterly Growth (%)